GCL
JSPRW icon

Glazer Capital LLC’s Japer Therapeutics Warrants JSPRW Stock Holding History

Glazer Capital LLC’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-162,234
Closed -$187K – 957
2021
Q2 		$187K Sell
162,234
-4,900
-3% -$4.64K ﹤0.01% 747
2021
Q1 		$137K Hold
167,134
– – ﹤0.01% 674
2020
Q4 		$242K Buy
167,134
+37,144
+29% +$46.6K 0.01% 330
2020
Q3 		$146K Hold
129,990
– – 0.01% 230
2020
Q2 		$130K Hold
129,990
– – 0.01% 151
2020
Q1 		$84K Buy
+129,990
New +$102K 0.01% 156

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Glazer Capital LLC's JSPRW Position: Q3 2021 in Review

Glazer Capital LLC sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2021, closing a stake of 162,234 shares — an estimated $187K sold.

Glazer Capital LLC first reported a position in JSPRW in Q1 2020 and held it in 6 quarters. The position peaked at $242K in Q4 2020. 16 funds tracked by Wall St. Rank hold JSPRW as of Q3 2021.

  • Glazer Capital LLC reported no remaining Japer Therapeutics Warrants position as of Q3 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 162,234 Japer Therapeutics Warrants shares in Q3 2021, an estimated $187K.
  • Glazer Capital LLC first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 6 quarters.
  • Glazer Capital LLC's Japer Therapeutics Warrants position peaked at $242K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2021.

Based on Glazer Capital LLC's 13F filing for Q3 2021, filed 15 Nov 2021.